SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
___________________
Date of Report (Date of earliest event reported) May 8, 1996
BIOCONTROL TECHNOLOGY, INC.
(Exact name of registrant as specified in its charter)
Pennsylvania 0-10822 25-1229323
(State of other jurisdiction (Commission File Number) (IRS Employer
of incorporation) Identification no.)
300 Indian Springs Road, Indiana, Pennsylvania 15701
(Address of principal executive offices) ( Zip Code)
Registrant's telephone number, including area code (412) 349-1811
_________________________________________________________________
(Former name or former address,
if changes since last report.)
Item 1. Change in Control of Registrant.
Not applicable.
Item 2. Acquisition or Disposition of Assets.
Not applicable.
Item 3. Bankruptcy or Receivership.
Not applicable.
Item 4. Changes in Registrant's Certifying Accountant
Not applicable.
Item 5. Other Events.
On May 8, 1996 Biocontrol Technology, Inc.
(NASDAQ:BICO) announced that its subsidiary, IDT,
Inc., in conjunction with HemoCleanse, Inc. of West
Lafayette, Indiana, has been given approval by the Food
and Drug Administration (FDA) for two sites to conduct
upcoming expanded studies of its extracorporeal whole-
body hypothermia therapy utilizing the BioLogic-HT
System for treatment of HIV/AIDS (WBHT). The sites are
Harbor-UCLA Research and Education Institute in Los
Angeles, California and St. Elizabeth Hospital in
Lafayette, Indiana.
Institutional Review Board (IRB) approval has been
granted by both sites, and studies are expected to
begin in 30 - 60 days at St. Elizabeth's.
In this expanded Phase II clinical trial, IDT
plans to further substantiate the safety of the
BioLogic-HT System and the efficacy of the WBHT. A
total of 60 patients will be randomly assigned to
participate in one of two groups: 1) 30 patients
receiving two treatments each (the first for one hour;
the second for two hours) at 42 C (107.6 F); and 2) 30
patients serving as a control group, receiving no WBHT
but remaining on standard HIV care. This will be the
first time patients have received a two-hour treatment,
which the Companies are hopeful will increase the viral
kill. Treatment involves artificially inducing a fever
by heating the blood while outside the body.
The BioLogic-HT System used in the procedure is
designed to meet the European Community (EC) standards
that allow it, and the disposables required with it, to
be marketed in all countries that are a part of the
EC. Marketing in the EC is underway, and several
European doctors will be visiting the US during the
upcoming trial to witness the procedure first-hand.
The Company has been informed that a lawsuit
proposing a class action against Biocontrol Technology,
Inc., Diasense, Inc., Fred E. Cooper, David L. Purdy
and Glenn Keeling was filed in federal court for the
Western District of Pennsylvania. The Company believes
that this action is without merit, and plans to
vigorously defend against the suit.
Item 6. Resignation of Registrant's Directors.
Not Applicable
Item 7. Financial Statement, Pro Forma Financial Information
and Exhibits.
(a) Financial Statements and Businesses Acquired - Not
Applicable.
(b) Pro Forma Financial Information - Not Applicable.
(c) Exhibits - News Release
SIGNATURES
Pursuant to the requirement of the Securities Exchange Act
of 1934, the Registrant has duly caused this Report to be signed
on its behalf by the undersigned hereunto duly authorized.
BIOCONTROL TECHNOLOGY, INC.
by /s/Fred E. Cooper
Fred E. Cooper, CEO
DATED: May 8, 1996
